Cardiovascular concerns are on the rise for people with diabetes, both in terms of acute and chronic complications, and a panel of scientists will discuss
A coordinated paradigm designed to overcome patient-, clinic-, and system-level barriers to care can significantly increase the prescribing of evidence-based drug therapies for people with
Retatrutide, a novel triple therapy, could continue the string of game-changing metabolic agents that began with semaglutide, a GLP-1 receptor agonist for type 2 diabetes
As part of the session “Where Lie the Keys to Type 2 Diabetes Prevention? Population Health or Personalized Medicine?”, This Paper Was Presented By Drs
As part of the session “Where Lie the Keys to Type 2 Diabetes Prevention? Population Health or Personalized Medicine?”, This Paper Was Presented By Drs
As part of the session “Are Two Better than One? Initial Combination Therapy in Type 2 Diabetes Mullites”, this paper was presented by Drs Alexandra
Today, the results of two studies demonstrate cutting-edge technology and the most recent diabetes advancements in relation to glucose control and diabetic retinopathy. Both investigations
The results of the ongoing clinical trial of VX- 880, a phase 1/2, multi-center, single-arm, openlabel study in patients with type 1 diabetes (T1D), were
The American Diabetes Association® published the Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes in 2021, which defined remission as “a return
Today, the results of SURMOUNT-2, a trial of tirzepatide in participants with type 2 diabetes and obesity, were released, revealing that the drug caused greater